ResMed reports Q2 FY2025 revenue up 10% to $1.28B; non-GAAP EPS $2.43, up 29%

RESMED INC

2025-Q2 EPS reported $4.45 revenue$2,506,598,000

Revenue $1.28B (+10% YoY); gross margin 58.6% (+300 bps) on manufacturing efficiencies.
Non-GAAP diluted EPS $2.43 (+29%); operating income $417M (+52% vs $275M, prior year had $64M restructuring).
Operating cash flow $309M; paid $78M dividends and repurchased $75M shares during quarter.
Board declared $0.53 quarterly dividend; record Feb 13, 2025, payable Mar 20, 2025.
Residential Care Software revenue up 8% constant currency; U.S./Canada/Latin America revenue up 12%.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.